Theravance Biopharma, Inc. Quarterly Operating Income (Loss) in USD from Q1 2013 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Theravance Biopharma, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2013 to Q3 2024.
  • Theravance Biopharma, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$10.8M, a 23.7% decline year-over-year.
  • Theravance Biopharma, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$44M, a 34.6% increase year-over-year.
  • Theravance Biopharma, Inc. annual Operating Income (Loss) for 2023 was -$56M, a 39.1% increase from 2022.
  • Theravance Biopharma, Inc. annual Operating Income (Loss) for 2022 was -$92M, a 64.3% increase from 2021.
  • Theravance Biopharma, Inc. annual Operating Income (Loss) for 2021 was -$258M, a 13.4% increase from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$44M -$10.8M -$2.08M -23.7% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-14
Q2 2024 -$41.9M -$15.7M +$418K +2.59% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-08
Q1 2024 -$42.3M -$11.2M +$13.7M +55% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-15
Q4 2023 -$56M -$6.24M +$11.2M +64.2% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-01
Q3 2023 -$67.2M -$8.76M +$384K +4.2% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-14
Q2 2023 -$67.6M -$16.1M +$10.8M +40% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 -$78.4M -$24.9M +$13.6M +35.3% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-15
Q4 2022 -$92M -$17.4M +$38.7M +69% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-01
Q3 2022 -$131M -$9.14M +$44.5M +82.9% Jul 1, 2022 Sep 30, 2022 10-K 2024-03-01
Q2 2022 -$175M -$26.9M +$37.2M +58.1% Apr 1, 2022 Jun 30, 2022 10-K 2024-03-01
Q1 2022 -$212M -$38.5M +$45.4M +54.1% Jan 1, 2022 Mar 31, 2022 10-K 2024-03-01
Q4 2021 -$258M -$56.2M +$20.3M +26.6% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-01
Q3 2021 -$278M -$53.6M +$23M +30% Jul 1, 2021 Sep 30, 2021 10-K 2023-03-01
Q2 2021 -$301M -$64.1M +$8.07M +11.2% Apr 1, 2021 Jun 30, 2021 10-K 2023-03-01
Q1 2021 -$309M -$83.9M -$11.4M -15.8% Jan 1, 2021 Mar 31, 2021 10-K 2023-03-01
Q4 2020 -$298M -$76.5M -$5.92M -8.39% Oct 1, 2020 Dec 31, 2020 10-K 2022-02-28
Q3 2020 -$292M -$76.6M -$11.4M -17.5% Jul 1, 2020 Sep 30, 2020 10-K 2022-02-28
Q2 2020 -$280M -$72.2M -$29.7M -69.9% Apr 1, 2020 Jun 30, 2020 10-K 2022-02-28
Q1 2020 -$251M -$72.5M +$1.19M +1.62% Jan 1, 2020 Mar 31, 2020 10-K 2022-02-28
Q4 2019 -$252M -$70.6M -$7.95M -12.7% Oct 1, 2019 Dec 31, 2019 10-K 2021-02-26
Q3 2019 -$244M -$65.2M -$2.75M -4.41% Jul 1, 2019 Sep 30, 2019 10-K 2021-02-26
Q2 2019 -$241M -$42.5M +$6.23M +12.8% Apr 1, 2019 Jun 30, 2019 10-K 2021-02-26
Q1 2019 -$247M -$73.7M -$8.69M -13.4% Jan 1, 2019 Mar 31, 2019 10-K 2021-02-26
Q4 2018 -$239M -$62.6M +$16.6M +20.9% Oct 1, 2018 Dec 31, 2018 10-K 2020-02-27
Q3 2018 -$255M -$62.5M -$5.45M -9.57% Jul 1, 2018 Sep 30, 2018 10-K 2020-02-27
Q2 2018 -$250M -$48.7M +$16.4M +25.2% Apr 1, 2018 Jun 30, 2018 10-K 2020-02-27
Q1 2018 -$266M -$65M -$6.15M -10.4% Jan 1, 2018 Mar 31, 2018 10-K 2020-02-27
Q4 2017 -$260M -$79.2M -$21.3M -36.9% Oct 1, 2017 Dec 31, 2017 10-K 2019-02-28
Q3 2017 -$239M -$57M -$23.5M -70.2% Jul 1, 2017 Sep 30, 2017 10-K 2019-02-28
Q2 2017 -$215M -$65.1M -$17.6M -37.1% Apr 1, 2017 Jun 30, 2017 10-K 2019-02-28
Q1 2017 -$198M -$58.8M -$17.2M -41.3% Jan 1, 2017 Mar 31, 2017 10-K 2019-02-28
Q4 2016 -$180M -$57.8M -$2.06M -3.69% Oct 1, 2016 Dec 31, 2016 10-K 2018-02-28
Q3 2016 -$178M -$33.5M +$9.6M +22.3% Jul 1, 2016 Sep 30, 2016 10-K 2018-02-28
Q2 2016 -$188M -$47.5M -$2.2M -4.87% Apr 1, 2016 Jun 30, 2016 10-K 2018-02-28
Q1 2016 -$186M -$41.6M -$3.91M -10.3% Jan 1, 2016 Mar 31, 2016 10-K 2018-02-28
Q4 2015 -$182M -$55.8M +$9.98M +15.2% Oct 1, 2015 Dec 31, 2015 10-K 2017-03-01
Q3 2015 -$192M -$43.1M +$6.97M +13.9% Jul 1, 2015 Sep 30, 2015 10-K 2017-03-01
Q2 2015 -$199M -$45.3M +$11.4M +20.1% Apr 1, 2015 Jun 30, 2015 10-K 2017-03-01
Q1 2015 -$210M -$37.7M +$22.3M +37.1% Jan 1, 2015 Mar 31, 2015 10-K 2017-03-01
Q4 2014 -$233M -$65.8M -$21.7M -49.2% Oct 1, 2014 Dec 31, 2014 10-K 2016-03-11
Q3 2014 -$211M -$50.1M -$8.98M -21.9% Jul 1, 2014 Sep 30, 2014 10-K 2016-03-11
Q2 2014 -$202M -$56.7M -$17.8M -45.6% Apr 1, 2014 Jun 30, 2014 10-K 2016-03-11
Q1 2014 -$184M -$60M -$27.8M -86.5% Jan 1, 2014 Mar 31, 2014 10-K 2016-03-11
Q4 2013 -$156M -$44.1M Oct 1, 2013 Dec 31, 2013 10-K 2015-03-13
Q3 2013 -$41.1M Jul 1, 2013 Sep 30, 2013 10-K 2015-03-13
Q2 2013 -$39M Apr 1, 2013 Jun 30, 2013 10-K 2015-03-13
Q1 2013 -$32.2M Jan 1, 2013 Mar 31, 2013 10-K 2015-03-13
* An asterisk sign (*) next to the value indicates that the value is likely invalid.